文献速递银屑病与炎症性皮肤病

培塞利珠单抗治疗中重度慢性斑块状银屑病患者:三项随机对照试验第16周数据的汇总分析

Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2018-10-14

汇总三项正在进行中的3期随机双盲安慰剂对照试验第16周数据,纳入850例中重度慢性斑块状银屑病患者,评估培塞利珠单抗400mg或200mg每2周一次疗效。第16周PASI 75和PGA 0/1应答率在400mg组为80.1%和63.7%,200mg组为74.5%和54.6%,安慰剂组为7.5%和2.8%(各剂量组与安慰剂比较P<0.0001)。有和无既往生物制剂治疗史患者中两剂量组应答率均高于安慰剂,安全性特征与抗TNF类一致。

要点

  • 培塞利珠单抗400mg或200mg每2周一次治疗16周,PASI 75和PGA 0/1应答率均显著高于安慰剂(P<0.0001)。
  • 有和无既往生物制剂治疗史的患者中,两剂量组应答率均 substantially 高于安慰剂。
  • 不良事件发生率400mg组与安慰剂组总体相似,200mg组略低于安慰剂组,未发现新安全性信号。

核心结论

  • 培塞利珠单抗400mg或200mg每2周一次治疗16周,在有和无既往生物制剂治疗史的中重度慢性斑块状银屑病患者中,与统计学显著且临床有意义的症状和体征改善相关,安全性特征与银屑病中抗TNF类一致。

研究设计与样本

  • 汇总三项正在进行中的3期随机双盲安慰剂对照试验的第16周数据。
  • 纳入年龄≥18岁、中重度慢性斑块状银屑病病程≥6个月的患者。
  • 患者随机接受培塞利珠单抗400mg、培塞利珠单抗200mg或安慰剂每2周一次治疗16周。
  • 汇总分析共纳入850例患者:培塞利珠单抗400mg组342例,培塞利珠单抗200mg组351例,安慰剂组157例。

主要发现

  • 第16周PASI 75应答率:培塞利珠单抗400mg组80.1%,200mg组74.5%,安慰剂组7.5%(各剂量组与安慰剂比较P<0.0001)。
  • 第16周PGA 0/1应答率:培塞利珠单抗400mg组63.7%,200mg组54.6%,安慰剂组2.8%(各剂量组与安慰剂比较P<0.0001)。
  • 有和无既往生物制剂治疗史的患者中,培塞利珠单抗两剂量组应答率均 substantially 高于安慰剂组。
  • 不良事件发生率在培塞利珠单抗400mg组与安慰剂组之间总体相似,200mg组略低于安慰剂组。
  • 未发现新的安全性信号。

关键数值与推荐

  • 共同主要终点为第16周应答率,定义为PASI较基线改善≥75%(PASI 75)和PGA评分为0或1(「清除」或「几乎清除」且改善≥2个等级)。
  • 安全性通过治疗中出现的不良事件评估。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Certolizumab pegol, an Fc-free, PEGylated, anti-tumour necrosis factor (TNF) biologic, has demonstrated favourable results in three ongoing, phase 3, randomized, double-blinded, placebo-controlled trials in adults with psoriasis. OBJECTIVE: Data were pooled from the ongoing trials to investigate efficacy in selected subgroups and add precision to estimates of treatment effects during the initial 16 weeks of treatment. METHODS: In each trial, patients ≥18 years with moderate-to-severe chronic plaque psoriasis for ≥6 months were randomized to receive certolizumab 400 mg, certolizumab 200 mg or placebo every 2 weeks for 16 weeks. Coprimary endpoints for the pooled analysis were responder rates at Week 16, defined as ≥75% reduction in psoriasis area and severity index (PASI 75) and physician global assessment (PGA) of 0/1 ('clear'/'almost clear' with ≥2-category improvement). Safety was assessed by treatment-emergent adverse events. RESULTS: A total of 850 patients treated with certolizumab 400 mg (N = 342), certolizumab 200 mg (N = 351) or placebo (N = 157) were included in the pooled analysis. At Week 16, PASI 75 and PGA 0/1 responder rates were 80.1% and 63.7% in the certolizumab 400 mg group, 74.5% and 54.6% in the certolizumab 200 mg group, and 7.5% and 2.8% in the placebo group (P < 0.0001 for each dose versus placebo). In patients with and without prior biologic therapy, both doses of certolizumab resulted in substantially higher responder rates versus placebo. The incidence of adverse events was generally similar between the 400 mg and placebo groups, and somewhat lower in the 200 mg group versus placebo. No new safety signals were identified. CONCLUSION: Certolizumab pegol 400 mg or 200 mg every 2 weeks for 16 weeks was associated with statistically significant and clinically meaningful improvements in signs and symptoms of psoriasis in patients with and without prior biologic therapy, and a safety profile consistent with the anti-TNF class in psoriasis.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Blauvelt A, Reich K, Lebwohl M, et al. Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials. J Eur Acad Dermatol Venereol. 2018. PMID: 30242918. doi:10.1111/jdv.15258

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。